BRAF and SPRY2

Data Source:
BioGRID (pull down, pull down)

		BRAF	SPRY2
Description		B-Raf proto-oncogene, serine/threonine kinase	sprouty RTK signaling antagonist 2
Image
GO Annotations	Cellular Component	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Nucleus Cytosol Cytoskeleton Plasma Membrane Actin Cytoskeleton Microtubule Cytoskeleton Membrane Ruffle Membrane Microtubule End
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity	Protein Binding Protein Kinase Binding Protein Serine/threonine Kinase Inhibitor Activity Protein Serine/threonine Kinase Activator Activity
	Biological Process	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	Establishment Of Mitotic Spindle Orientation Sensory Perception Of Sound Negative Regulation Of Cell Population Proliferation Positive Regulation Of Gene Expression Negative Regulation Of Epithelial To Mesenchymal Transition Negative Regulation Of Peptidyl-threonine Phosphorylation Negative Regulation Of Angiogenesis Positive Regulation Of Cell Migration Negative Regulation Of Transforming Growth Factor Beta Receptor Signaling Pathway Negative Regulation Of Cell Projection Organization Negative Regulation Of Protein Ubiquitination Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of GTPase Activity Cellular Response To Vascular Endothelial Growth Factor Stimulus Negative Regulation Of Fibroblast Growth Factor Receptor Signaling Pathway Negative Regulation Of Epidermal Growth Factor Receptor Signaling Pathway Inner Ear Morphogenesis Negative Regulation Of Apoptotic Process Negative Regulation Of MAP Kinase Activity Cell Fate Commitment Negative Regulation Of Ras Protein Signal Transduction Animal Organ Development Negative Regulation Of Neurotrophin TRK Receptor Signaling Pathway Positive Regulation Of Protein Kinase B Signaling Lung Growth Bud Elongation Involved In Lung Branching Negative Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Protein Serine/threonine Kinase Activity Negative Regulation Of Vascular Endothelial Growth Factor Signaling Pathway Negative Regulation Of Lens Fiber Cell Differentiation Cellular Response To Leukemia Inhibitory Factor
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	Spry regulation of FGF signaling EGFR downregulation
Drugs		Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)	Adiposity ( 21706003) Adventurousness ( 30643258) Body fat percentage ( 26833246) Central corneal thickness ( 32528159) Cleft lip with or without cleft palate ( 28054174) Diastolic blood pressure ( 30224653) Fasting blood insulin (BMI interaction) ( 22581228) General risk tolerance (MTAG) ( 30643258) Height ( 25282103 31562340) Insulin-related traits (multivariate analysis) ( 32002517) Lactose tolerance test ( 31791255) Leisure-time exercise behaviour (age-stratified) ( 30102679) Medication use (drugs used in diabetes) ( 31015401) Methadone dose in opioid dependence ( 28115739) Nonsyndromic cleft lip with cleft palate ( 28232668) Orofacial clefts ( 20023658 22863734 28054174) Response to inhaled corticosteroid treatment in asthma (change in FEV1) ( 24792382) Sleep duration ( 25469926) Thrombocytopenia in coronary artery bypass surgery ( 30103242) Type 2 diabetes ( 22885922 24509480 30054458 20862305 29358691 30297969 26818947 31118516 32499647 30718926 28869590) Venous thromboembolism adjusted for sickle cell variant rs77121243-T ( 28203683)
Interacting Genes		46 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510	105 interacting genes: ADAMTSL4 AQP1 ATRIP BAG3 BRAF CATSPER1 CBL CBLB CBLC CHRD CHRNG CREB5 CRIP2 CRMP1 CSTB CTSB DGCR6 DNM2 EIF4E2 FAIM FAM219A FBN1 FBXO7 FRS3 GNE GP9 GPRIN2 GRAP2 GRB2 GRN HEXIM2 HNRNPLL HOXA1 HSD3B7 ITSN1 KDM1A KIF1A KRTAP10-1 KRTAP10-11 KRTAP10-3 KRTAP10-5 KRTAP10-8 KRTAP10-9 KRTAP4-11 KRTAP4-12 KRTAP4-7 KRTAP5-6 KRTAP5-9 KRTAP9-2 KRTAP9-4 LASP1 LCE1A LCE1B LCE1C LCE1F LCE2D LCE3C LCE3E LCE4A LONRF1 MAPKBP1 MB21D2 MDFI MEOX2 MID2 MKNK1 MLLT6 NCK2 NEDD4 NR1H2 NUBP1 OTX1 PACSIN3 PLSCR1 PRKAB2 PRKCD PRKD1 PTGER3 PTPN11 RAF1 RTF2 RUNX1T1 SDHB SEMA5B SH3KBP1 SHFL SIAH2 SPRY1 STK16 TCAF1 TMEM14B TNS2 TRAF2 TRIM51 TXNDC5 UBASH3A UBASH3B UBR1 USP20 VPS25 VPS36 ZBTB16 ZNF266 ZNF417 ZNF587
Entrez ID		673	10253
HPRD ID		01264	03916
Ensembl ID		ENSG00000157764	ENSG00000136158
Uniprot IDs		P15056	O43597
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6XAG	3BUM 3OB1 5HKY 5HKZ 5HL0
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?